Short sellers have been moving aggressively into SOLV ahead of its May 5 Q1 earnings report — and the speed of that build is the defining feature of this setup.
Short interest has nearly doubled over the past month, rising 64% to 3.99% of the free float. The week-on-week jump alone is 20%. Borrow availability remains loose — the lending pool is far from exhausted, and the cost to borrow is a negligible 0.52% — so this isn't a squeeze-pressure story. It reads instead as a deliberate directional bet, with shorts adding conviction ahead of the print rather than being forced out.
Options positioning reinforces a cautious tone, without screaming alarm. The put/call ratio has drifted up to 0.46, above its 20-day average of 0.39, though it remains well clear of its 52-week high of 0.75. That's mildly more defensive than normal — a hedge, not a panic. Price action has done little to settle nerves: the stock is down 2.8% on the week to $66.63, after a modest 2% bounce over the past month from lows near $62.
The bull-bear divide on SOLV is structural. Bulls point to growth in the MedSurg segment, antimicrobial product adoption, and expanding Revenue Cycle Management capabilities as levers that could demonstrate a turnaround from years of negative volume growth. Bears have the harder facts on their side: seven consecutive quarters of volume decline before the spin-off, and a gross margin headwind of roughly 40 basis points in 2026 tied to tariff exposure. Recent analyst moves reflect a Street that still sees upside but is trimming its ambitions. Keybanc lowered its target to $92 on April 27 while holding Overweight; Piper Sandler cut to $92 two weeks prior. The mean target of $84 implies roughly 26% upside to the current price — but Rothschild, which initiated in late March, placed a Sell with a $60 target, essentially flagging the stock as fairly valued or worse at current levels.
One ownership note is worth flagging. Independent Franchise Partners added 2.46 million shares in Q1, lifting its stake to 8.9% of the company. Davis Selected Advisers added 702,000 shares in the same quarter. That active-manager accumulation provides a counterweight to the short build — long-term holders are moving in the opposite direction from the near-term bearish positioning.
The Q1 print will therefore test whether Solventum's management can offer any credible sign of volume stabilisation — and whether the margin trajectory, under tariff pressure, is deteriorating faster than even the bears have priced in.
See the live data behind this article on ORTEX.
Open SOLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
